Literature DB >> 30165415

The Extended Impact of Human Immunodeficiency Virus/AIDS Research.

Tara A Schwetz1, Anthony S Fauci1.   

Abstract

Human immunodeficiency virus (HIV) is one of the most extensively studied viruses in history, and numerous extraordinary scientific advances, including an in-depth understanding of viral biology, pathogenesis, and life-saving antiretroviral therapies, have resulted from investments in HIV/AIDS research. While the substantial investments in HIV/AIDS research are validated solely on these advances, the collateral broader scientific progress resulting from the support of HIV/AIDS research over the past 30 years is extraordinary as well. The positive impact has ranged from innovations in basic immunology and structural biology to treatments for immune-mediated diseases and cancer and has had an enormous effect on the research and public and global health communities well beyond the field of HIV/AIDS. This article highlights a few select examples of the unanticipated and substantial positive spin-offs of HIV/AIDS research on other scientific areas.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30165415      PMCID: PMC6455931          DOI: 10.1093/infdis/jiy441

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  23 in total

Review 1.  HIV infection and neoplasia.

Authors:  T F Schulz; C H Boshoff; R A Weiss
Journal:  Lancet       Date:  1996-08-31       Impact factor: 79.321

Review 2.  Aging and HIV/AIDS: pathogenetic role of therapeutic side effects.

Authors:  Rebecca A Torres; William Lewis
Journal:  Lab Invest       Date:  2013-12-16       Impact factor: 5.662

3.  Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection.

Authors:  Jens D Lundgren; Abdel G Babiker; Fred Gordin; Sean Emery; Birgit Grund; Shweta Sharma; Anchalee Avihingsanon; David A Cooper; Gerd Fätkenheuer; Josep M Llibre; Jean-Michel Molina; Paula Munderi; Mauro Schechter; Robin Wood; Karin L Klingman; Simon Collins; H Clifford Lane; Andrew N Phillips; James D Neaton
Journal:  N Engl J Med       Date:  2015-07-20       Impact factor: 91.245

Review 4.  HIV-associated chronic immune activation.

Authors:  Mirko Paiardini; Michaela Müller-Trutwin
Journal:  Immunol Rev       Date:  2013-07       Impact factor: 12.988

Review 5.  Deep sequencing and human antibody repertoire analysis.

Authors:  Scott D Boyd; James E Crowe
Journal:  Curr Opin Immunol       Date:  2016-04-08       Impact factor: 7.486

6.  The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus.

Authors:  A G Dalgleish; P C Beverley; P R Clapham; D H Crawford; M F Greaves; R A Weiss
Journal:  Nature       Date:  1984 Dec 20-1985 Jan 2       Impact factor: 49.962

7.  The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial.

Authors:  M A Fischl; D D Richman; M H Grieco; M S Gottlieb; P A Volberding; O L Laskin; J M Leedom; J E Groopman; D Mildvan; R T Schooley
Journal:  N Engl J Med       Date:  1987-07-23       Impact factor: 91.245

Review 8.  Antiviral resistance and the future landscape of hepatitis C virus infection therapy.

Authors:  David L Wyles
Journal:  J Infect Dis       Date:  2013-03       Impact factor: 5.226

9.  Broadly neutralizing antibodies from human survivors target a conserved site in the Ebola virus glycoprotein HR2-MPER region.

Authors:  Andrew I Flyak; Natalia Kuzmina; Charles D Murin; Christopher Bryan; Edgar Davidson; Pavlo Gilchuk; Christopher P Gulka; Philipp A Ilinykh; Xiaoli Shen; Kai Huang; Palaniappan Ramanathan; Hannah Turner; Marnie L Fusco; Rebecca Lampley; Nurgun Kose; Hannah King; Gopal Sapparapu; Benjamin J Doranz; Thomas G Ksiazek; David W Wright; Erica Ollmann Saphire; Andrew B Ward; Alexander Bukreyev; James E Crowe
Journal:  Nat Microbiol       Date:  2018-05-07       Impact factor: 17.745

10.  Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada.

Authors:  Hasina Samji; Angela Cescon; Robert S Hogg; Sharada P Modur; Keri N Althoff; Kate Buchacz; Ann N Burchell; Mardge Cohen; Kelly A Gebo; M John Gill; Amy Justice; Gregory Kirk; Marina B Klein; P Todd Korthuis; Jeff Martin; Sonia Napravnik; Sean B Rourke; Timothy R Sterling; Michael J Silverberg; Stephen Deeks; Lisa P Jacobson; Ronald J Bosch; Mari M Kitahata; James J Goedert; Richard Moore; Stephen J Gange
Journal:  PLoS One       Date:  2013-12-18       Impact factor: 3.240

View more
  4 in total

Review 1.  Emergence and molecular mechanisms of SARS-CoV-2 and HIV to target host cells and potential therapeutics.

Authors:  Mansab Ali Saleemi; Bilal Ahmad; Khaled Benchoula; Muhammad Sufyan Vohra; Hing Jian Mea; Pei Pei Chong; Navindra Kumari Palanisamy; Eng Hwa Wong
Journal:  Infect Genet Evol       Date:  2020-10-06       Impact factor: 3.342

Review 2.  Emerging paradigms of viral diseases and paramount role of natural resources as antiviral agents.

Authors:  R Sagaya Jansi; Ameer Khusro; Paul Agastian; Ahmed Alfarhan; Naif Abdullah Al-Dhabi; Mariadhas Valan Arasu; Rajakrishnan Rajagopal; Damia Barcelo; Amal Al-Tamimi
Journal:  Sci Total Environ       Date:  2020-11-07       Impact factor: 7.963

Review 3.  Lessons Learned and Yet-to-Be Learned on the Importance of RNA Structure in SARS-CoV-2 Replication.

Authors:  Maclean Bassett; Marco Salemi; Brittany Rife Magalis
Journal:  Microbiol Mol Biol Rev       Date:  2022-07-07       Impact factor: 13.044

Review 4.  Novel Psychoactive Substances: The Razor's Edge between Therapeutical Potential and Psychoactive Recreational Misuse.

Authors:  Beatriz Correia; Joana Fernandes; Maria João Botica; Carla Ferreira; Alexandre Quintas
Journal:  Medicines (Basel)       Date:  2022-03-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.